Economies of scale in experimentation: knowledge and technology in pharmaceutical R&D.

Nightingale, Paul (2000) Economies of scale in experimentation: knowledge and technology in pharmaceutical R&D. Industrial and Corporate Change, 9 (2). pp. 315-359. ISSN 0960-6491

Full text not available from this repository.

Abstract

This paper explores how changes in genetics, database, high-throughput screening and bioinformatics technologies have allowed pharmaceutical firms to exploit economies of scale in experimentation. Traditional craft-based, sequential experimentation in chemistry and biology has been complemented by firstly, the automated, mass-production analysis of populations and secondly, by 'in silico' experimentation using simulations and databases. The changes are analysed within a Chandlerian framework that highlights how increases in the 'throughput' of R&D are dependent on organizational and managerial responses to systemic uncertainty.

Item Type: Article
Schools and Departments: School of Business, Management and Economics > SPRU - Science Policy Research Unit
Depositing User: Paul Nightingale
Date Deposited: 06 Feb 2012 20:16
Last Modified: 06 Feb 2012 21:52
URI: http://sro.sussex.ac.uk/id/eprint/25131
📧 Request an update